BTK inhibitor GB-7208 shows promise for treating multiple sclerosis relapse
Feb. 27, 2023
Therapies for multiple sclerosis (MS) have been effective in relapse prevention but emerging data still show the continued disability progression independent of relapse activity (PIRA), characterized by the presence of ectopic B-cell follicles and active lesions with microglia cells, resulting in a smoldering central nervous system (CNS)-driven inflammation, tissue damage and disease progression.